SCHEMBL4083380

SCHEMBL4083380

CC(C)[Si](OC1CN([C@H](C)c2ccccc2)CC=C1c1ccc(OCc2ccccc2)cc1)(C(C)C)C(C)C

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FDFT1 P37268 1/20 0.46
CHRM4 P08173 1/20 0.42
PRMT5 O14744 4/20 0.38
BCHE P06276 2/20 0.37
ALOX5 P09917 2/20 0.37
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
RAB9A P51151 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
ACACB O00763 1/20 0.36
BCL2 P10415 1/20 0.36
MDM2 Q00987 1/20 0.36
MCL1 Q07820 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2682972 1.00 FDFT1 (0.46) FDFT1CHRM4PRMT5BCHEALOX5
SCHEMBL4083377 1.00 FDFT1 (0.46) FDFT1CHRM4PRMT5BCHEALOX5
SCHEMBL6622776 0.87 FDFT1 (0.44) FDFT1CHRM4BCHEALOX5NPC1
SCHEMBL8218213 0.84 FDFT1 (0.47) FDFT1CHRM4BCHEALOX5NPC1
SCHEMBL1941467 0.84 FDFT1 (0.47) FDFT1CHRM4BCHEALOX5NPC1
SCHEMBL8218218 0.84 FDFT1 (0.47) FDFT1CHRM4BCHEALOX5NPC1
SCHEMBL4602100 0.76 HRH3 (0.49) FDFT1CHRM4PRMT5BCHENPC1
SCHEMBL4602103 0.76 HRH3 (0.49) FDFT1CHRM4PRMT5BCHENPC1
SCHEMBL2683449 0.73 CHRM4 (0.42) CHRM4BCHEALOX5NPC1RAB9A
SCHEMBL2338156 0.73 CHRM4 (0.42) CHRM4BCHEALOX5NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270380-A1 3,4,5-Substituted Piperidines as Renin Inhibitors NOVARTIS AG (CH) 2009-10-29 US disclosed
US-20090029981-A1 SUBSTITUTED 4-PHENYLPIPERIDINES NOVARTIS AG (CH) 2009-01-29 US disclosed
EP-2018862-A1 Substituted piperidines as therapeutic compounds Speedel Experimenta AG (CH) 2009-01-28 EP disclosed
EP-1973903-A1 SUBSTITUTED 4-PHENYLPIPERIDINES Speedel Experimenta AG (CH) 2008-10-01 EP disclosed
EP-1908762-A2 Organic compounds Speedel Experimenta AG (CH) 2008-04-09 EP disclosed
EP-1908761-A1 Organic compounds Speedel Experimenta AG (CH) 2008-04-09 EP disclosed
EP-1863763-A1 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS Speedel Experimenta AG (CH) 2007-12-12 EP disclosed
EP-1816122-A2 3,4,5-substituted piperidines as therapeutic compounds Speedel Experimenta AG (CH) 2007-08-08 EP disclosed
WO-2007082907-A1 SUBSTITUTED 4-PHENYLPIPERIDINES SPEEDEL EXPERIMENTA AG (CH) 2007-07-26 WO disclosed
US-20070167433-A1 3,4,5-Substituted piperidines as therapeutic compounds SPEEDEL EXPERIMENTA AG (CH) 2007-07-19 US disclosed
WO-2006103275-A1 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS SPEEDEL EXPERIMENTA AG (CH) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167433-A1 3,4,5-Substituted piperidines as therapeutic compounds CTSD, CTSL, CTSZ FDFT1 4813/4885CHRM4 2037/4885PRMT5 560/4885
US-20090270380-A1 3,4,5-Substituted Piperidines as Renin Inhibitors REN, AGTR1, AGTR2 FDFT1 4831/4885CHRM4 445/4885PRMT5 39/4885
US-20090029981-A1 SUBSTITUTED 4-PHENYLPIPERIDINES REN, AGTR2, ACE FDFT1 4767/4885CHRM4 759/4885PRMT5 1175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.